[go: up one dir, main page]

MX2010003574A - Anticuerpos il-23. - Google Patents

Anticuerpos il-23.

Info

Publication number
MX2010003574A
MX2010003574A MX2010003574A MX2010003574A MX2010003574A MX 2010003574 A MX2010003574 A MX 2010003574A MX 2010003574 A MX2010003574 A MX 2010003574A MX 2010003574 A MX2010003574 A MX 2010003574A MX 2010003574 A MX2010003574 A MX 2010003574A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding proteins
antibodies
prophylaxis
human
Prior art date
Application number
MX2010003574A
Other languages
English (en)
Inventor
Paul Andrew Hamblin
Gary Peter Bembridge
Jonathan Henry Ellis
Ruth Mcadam
Alan Peter Lewis
George Kopsidas
Jane Elizabeth Clarkson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40378889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003574(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2010003574A publication Critical patent/MX2010003574A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invenci?n se refiere a prote?nas que se unen a ant?genos contra IL-23 humana, formulaciones farmac?uticas que las contienen y al uso de dichas prote?nas que se unen a ant?genos en el tratamiento y/o profilaxis de enfermedades inflamatorias tales como artritis reumatoide (RA).
MX2010003574A 2007-10-05 2008-10-03 Anticuerpos il-23. MX2010003574A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97784107P 2007-10-05 2007-10-05
PCT/EP2008/063289 WO2009043933A1 (en) 2007-10-05 2008-10-03 Il-23 antibodies

Publications (1)

Publication Number Publication Date
MX2010003574A true MX2010003574A (es) 2010-04-22

Family

ID=40378889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003574A MX2010003574A (es) 2007-10-05 2008-10-03 Anticuerpos il-23.

Country Status (16)

Country Link
US (2) US20090123479A1 (es)
EP (1) EP2205637A1 (es)
JP (1) JP2011501738A (es)
KR (1) KR20100097654A (es)
CN (1) CN101889026A (es)
AR (1) AR068723A1 (es)
AU (1) AU2008306850A1 (es)
BR (1) BRPI0818620A2 (es)
CA (1) CA2700758A1 (es)
CL (1) CL2008002952A1 (es)
EA (1) EA201000424A1 (es)
MX (1) MX2010003574A (es)
PE (1) PE20091342A1 (es)
TW (1) TW200930729A (es)
WO (1) WO2009043933A1 (es)
ZA (1) ZA201002275B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101663320A (zh) 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
EP2310415B8 (en) 2008-04-25 2017-12-13 Dyax Corp. Antibodies against fcrn and use thereof
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
EP2414393A1 (en) * 2009-04-01 2012-02-08 Glaxo Group Limited Anti-il-23 immunoglobulins
EP2480251B1 (en) 2009-09-21 2025-12-03 Peptinov Carrier conjugates of il-23-peptides and their induced antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
EP2966089B1 (en) * 2011-06-02 2020-03-25 Dyax Corp. Fc receptor binding proteins
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
EP3441400B1 (en) * 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EA031025B1 (ru) * 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
HK1219425A1 (zh) 2013-03-15 2017-04-07 Amgen Inc. 使用抗il-23抗体治疗银屑病的方法
CN105307675A (zh) 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
RU2723034C2 (ru) 2014-05-22 2020-06-08 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые полипептиды со специфическим связыванием и пути их применения
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
SG11201705728RA (en) 2015-02-04 2017-08-30 Boehringer Ingelheim Int Methods of treating inflammatory diseases
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
EP3368569B1 (en) 2015-10-30 2021-02-24 Ablynx NV Polypeptides against il-23
CN109154611B (zh) 2015-12-09 2022-04-08 科尔沃斯制药股份有限公司 人源化抗cd73抗体
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3773718A4 (en) 2018-04-06 2022-01-19 aTyr Pharma, Inc. COMPOSITIONS AND METHODS WITH ANTI-NRP2 ANTIBODIES
EA202190197A1 (ru) 2018-07-13 2021-04-26 Астразенека Коллаборэйшн Венчерз, Ллс Лечение язвенного колита с помощью бразикумаба
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
EP4037711A4 (en) 2019-10-03 2024-02-14 Atyr Pharma, Inc. COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES
CN115135671A (zh) 2019-12-20 2022-09-30 新石生物制药有限公司 抗白介素-23 p19的抗体及其使用方法
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途
EP4423142A4 (en) * 2021-10-27 2025-10-22 Atyr Pharma Inc COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2A ANTIBODIES
CN114920830B (zh) * 2022-05-07 2023-05-16 北京大学 Vκ4-1-IgLC多肽及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI439285B (zh) * 2003-03-10 2014-06-01 Merck Sharp & Dohme Ｉｌ－２３激動劑及拮抗劑之用途及相關試劑
PT1896073E (pt) * 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
ES2347690T3 (es) * 2005-08-25 2010-11-03 Eli Lilly And Company Anticuerpos anti-il-23.
ME02705B (me) * 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela

Also Published As

Publication number Publication date
AU2008306850A1 (en) 2009-04-09
PE20091342A1 (es) 2009-09-16
EA201000424A1 (ru) 2010-10-29
BRPI0818620A2 (pt) 2019-09-24
ZA201002275B (en) 2011-06-29
US20090123479A1 (en) 2009-05-14
JP2011501738A (ja) 2011-01-13
CN101889026A (zh) 2010-11-17
TW200930729A (en) 2009-07-16
KR20100097654A (ko) 2010-09-03
AR068723A1 (es) 2009-12-02
CL2008002952A1 (es) 2009-10-16
EP2205637A1 (en) 2010-07-14
US20110206686A1 (en) 2011-08-25
WO2009043933A1 (en) 2009-04-09
CA2700758A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
MX2010003574A (es) Anticuerpos il-23.
MX2011012622A (es) Proteina de enlace de il-13.
WO2008121615A3 (en) Antibody formulation
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
NZ599875A (en) Human il-23 antigen binding proteins
PH12012501549A1 (en) Cd127 binding proteins
UA100682C2 (ru) АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
EP2614085A4 (en) ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE
EA200870129A1 (ru) Человеческие антитела против il-23, композиции, способы и применение
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
PT2126049E (pt) Anticorpos contra citomegalovírus humano (hcmv)
UA92505C2 (ru) Композиции на основе антитела против cd3
MY185813A (en) Factor xi antibodies and methods of use
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL194550A (en) Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
UA105384C2 (ru) Лечение нарушений, связанных с инсулинорезистентностью
TW200801038A (en) Immunoglobulins
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal